Printer Friendly

NOVA PHARMACEUTICAL BEGINS HUMAN TESTING ON TREATMENT FOR INFLAMMATORY CONDITIONS; TARGET SEPSIS/SEPTIC SHOCK, INFLAMMATORY BOWEL DISEASE

NOVA PHARMACEUTICAL BEGINS HUMAN TESTING ON TREATMENT FOR INFLAMMATORY
 CONDITIONS; TARGET SEPSIS/SEPTIC SHOCK, INFLAMMATORY BOWEL DISEASE
 BALTIMORE, May 19 /PRNewswire/ -- Nova Pharmaceutical Corporation (NASDAQ: NOVX) today announced at its annual meeting of shareholders that it has begun Phase I clinical testing of the company's leumedin anti-inflammatory compound, NPC 15669, for the treatment of two medical conditions: sepsis/septic shock and inflammatory bowel disease. Phase I clinical studies are designed to evaluate the safety of an experimental treatment in healthy volunteers.
 Septic shock can occur following an overwhelming bacterial infection (sepsis) and is characterized by fever, low white blood cell count, low blood pressure, and multiple organ failure. Each year approximately 400,000 patients in the United States develop sepsis, a leading cause of mortality among hospitalized patients.
 In preclinical models, the leumedin compound NPC 15669 has been shown to be active against experimental forms of septic shock. Because of the mechanism of action of the leumedins, NPC 15669 is expected to inhibit shock associated with gram-negative or gram-positive sepsis.
 Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract. An estimated 475,000 patients in the United States suffer from IBD. In preclinical models, Nova's leumedin compound, NPC 15669, significantly reduced experimentally induced inflammation of the lower bowel.
 "The leumedin project has been a major focus of Nova's research and development effort during the past two years, and we have been very pleased with the results of preclinical studies," said Dr. Hans Mueller, Nova president and chief executive officer. "We look forward to the opportunity to evaluate a leumedin compound in a clinical setting."
 In January 1991, Nova scientists published the discovery of the leumedins, a new class of anti-inflammatory drugs which act by a novel mechanism. These drugs interfere with adhesion molecules which are responsible for the migration of white blood cells from blood vessels into tissues to initiate inflammation. The leumedins are the first non- protein class of drugs to exert anti-inflammatory effects via this mechanism, and are effective in reversing inflammatory symptoms in numerous preclinical disease models. Examples of such diseases include rheumatoid arthritis, IBD, and contact dermatitis.
 Nova Pharmaceutical Corporation, based in Baltimore, is engaged in the discovery, development, and commercialization of pharmaceutical products which address areas of significant medical need. The company's research and development programs are in three principal areas: inflammation, central nervous system disorders, and drug delivery systems. The company's scientific strategy is to employ the tools of receptor technology, rational drug design, and drug delivery technologies to develop novel therapeutic products.
 -0- 5/19/92
 /CONTACT: Kira Bacon of Nova, 410-558-9465, or Noonan/Russo Communications, 212-979-9180, for Nova/
 (NOVX) CO: Nova Pharmaceutical Corporation ST: Maryland IN: MTC SU:


PS-KD -- NY041 -- 1755 05/19/92 11:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:459
Previous Article:CABLE SERVICES GROUP SELECTS IBM INFORMATION NETWORK TO CONNECT CABLE TELEVISION COMPANIES NATIONWIDE
Next Article:SOUTHWEST AIRLINES ANNOUNCES ANNUAL MEETING
Topics:


Related Articles
IMMUNEX IL-1 RECEPTOR CLINICAL TRIALS BEGIN; FIRST STEP IN AGGRESSIVE CLINICAL RESEARCH PROGRAM
SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL
IMMUNEX BEGINS SOLUBLE TNF RECEPTOR TRIALS; NIH LAUNCHES FIRST STUDY IN SEPSIS PATIENTS
LIPOSOME COMPANY'S FOURTH DRUG ENTERS CLINICAL TRIALS; BEING DEVELOPED TO TREAT OFT-FATAL LUNG DISEASE
SYNERGEN FILES EUROPEAN MARKETING APPLICATION FOR ANTRIL IN SEVERE SEPSIS
ISIS PHARMACEUTICALS COMMENCES CLINICAL TRIALS FOR ANTISENSE DRUG TO INHIBIT ICAM-1
ISIS STUDY SHOWS ANTISENSE COMPOUND
ISIS INITIATES PHASE II CLINICAL TRIALS OF ISIS 2302, AN ANTISENSE COMPOUND TO TREAT INFLAMMATORY DISEASES
CELGENE SCIENTISTS REVEAL NEW THALIDOMIDE-RELATED DRUGS AT AMERICAN CHEMICAL SOCIETY'S 210TH NATIONAL MEETING
US FDA AUTHORIZES CELGENE TO PROVIDE EXPANDED ACCESS TO SYNOVIR (THALIDOMIDE) FOR AIDS-ASSOCIATED WASTING

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters